Impact of body weight on efficacy of tildrakizumab in moderate to severe plaque psoriasis

被引：0

作者：

Leonardi, Craig ^{[1
,2
]}

Menter, Alan M. ^{[3
,4
]}

Draelos, Zoe ^{[5
]}

Heim, Jayme ^{[6
]}

Parno, Jeff ^{[7
]}

Mendelsohn, Alan M. ^{[7
]}

Rozzo, Stephen J. ^{[7
]}

Griffiths, Christopher E. M. ^{[8
]}

机构：

[1] Cent Dermatol, St Louis, MO USA

[2] St Louis Univ, Sch Med, St Louis, MO USA

[3] Baylor Scott & White, Div Dermatol, Dallas, TX USA

[4] Texas A&M Coll Med, Dallas, TX USA

[5] Dermatol Consulting Serv, High Point, NC USA

[6] West Michigan Dermatol, Holland, MI USA

[7] Sun Pharmaceut Ind Inc, Princeton, NJ USA

[8] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester, Lancs, England

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

10089

引用

页码：AB76 / AB76

页数：1

共 50 条

[1] Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis
Menter, Alan
Draelos, Zoe
Heim, Jayme
Parno, Jeff
Mendelsohn, Alan
Rozzo, Stephen
Griffiths, Christopher
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[2] Impact of body weight on efficacy of tildrakizumab at week 12 in moderate to severe chronic plaque psoriasis
Blauvelt, A.
Kimball, A.
Papp, K.
Reich, K.
Tyring, S.
Sinclair, R.
Thaci, D.
Li, Q.
Cichanowitz, N.
Green, S.
La Rosa, C.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 109 - 110
[3] Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis
Frampton, James E.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (02) : 295 - 306
[4] Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis
James E. Frampton
American Journal of Clinical Dermatology, 2019, 20 : 295 - 306
[5] Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis
Elewski, Boni
Menter, Alan
Crowley, Jeffrey
Tyring, Stephen
Zhao, Yang
Lowry, Simon
Rozzo, Stephen
Mendelsohn, Alan M.
Parno, Jeffrey
Gordon, Kenneth
JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (08) : 763 - 768
[6] PREDICTORS OF RESPONSE TO TILDRAKIZUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Blauvelt, Andrew
Reich, Kristian
Papp, Kim A.
Tyring, Stephen K.
Sinclair, Rodney
Thaci, Diamant
Gooderham, Melinda
Li, Qing
Cichanowitz, Nicole
La Rosa, Carmen
ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 22 - 22
[7] INCIDENCE OF INFECTIONS IN CLINICAL TRIALS OF TILDRAKIZUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS
Crowley, Jeffrey
Leonardi, Craig
Sturgill-Koszycki, Sheila
Menter, Alan
Mendelsohn, Alan
Li, Qing
Cichanowitz, Nicole
La Rosa, Carmen
ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 28 - 28
[8] Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature
Kory P. Schrom
Avi Bitterman
Neil J. Korman
Current Dermatology Reports, 2019, 8 : 6 - 13
[9] Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature
Schrom, Kory P.
Bitterman, Avi
Korman, Neil J.
CURRENT DERMATOLOGY REPORTS, 2019, 8 (01) : 6 - 13
[10] Predictors of response to tildrakizumab for moderate-to-severe chronic plaque psoriasis
Blauvelt, Andrew
Reich, Kristian
Papp, Kim A.
Tyring, Stephen K.
Sinclair, Rodney
Thaci, Diamant
Gooderham, Melinda
Li, Qing
Cichanowitz, Nicole
la Rosa, Carmen
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB226 - AB226

← 1 2 3 4 5 →